The DOI matches its Crossref record; 117 of the 117 references it cites were found in a registry or an index.
Clinical and biologic relevance of immunologic marker studies in childhood acute lymphoblastic leukemia
Abstract
Immunologic marker studies of the lymphoid leukemias have greatly improved the precision of diagnosis of these disorders by providing specific information regarding the lineage and stage of maturation of the malignant cells. Such studies have also enhanced our understanding of normal lymphocyte development, permitting reproducible identification of lymphoid cells in discrete developmental stages. By elucidating the functions of lymphoid cell differentiation antigens, it has been possible to gain insight into the signal transduction mechanisms by which these cells interact among themselves and with other cell types. Similar studies have shown that ALL is an immunophenotypically heterogeneous disease with clinically important subtypes representing clonal expansions of lymphoblasts at different stages of maturation. Furthermore, successful correlation of immunophenotype with certain karyotypic and molecular abnormalities, which appear to underlie most or all leukemias, were made possible by the inclusion of immunologic marker assessment. Interestingly, many of these phenotype-related abnormalities have involved either the Ig or TCR genes, thus providing additional clues to the mechanisms of leukemogenesis. Knowledge of the immunologic features of leukemic cells has been essential for the generation of phenotype-specific response data in the context of modern therapy for ALL. With wider use of intensive treatment, the traditional prognostic distinctions among immunophenotypes have begun to disappear; however, certain classes of agents have more favorable toxicity/efficacy ratios against some immunophenotypes than others, justifying continued efforts to target therapy by immunologic species of ALL. Antibody-toxin conjugates, or immunotoxins, have induced complete responses in preliminary trials and may prove clinically useful, perhaps in combination with chemotherapy, if their toxic side effects can be controlled. Finally, immunologic markers may serve as sensitive targets for the detection of minimal residual disease; the clinical usefulness of this approach will depend on prospective comparisons with molecular methods.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
1 retracted
Huang, S., & Terstappen, L. W. M. M. (1992) · Nature · doi:10.1038/360745a0 · Cited by 186
RetractedContinuous cultures of fused cells secreting antibody of predefined specificity
KÖHLER, G., & MILSTEIN, C. (1975) · Nature · doi:10.1038/256495a0 · Cited by 17,229
Bennett, J. M., Catovsky, D., Daniel, M., Flandrin, G., Galton, D. A. G., Gralnick, H. R., & Sultan, C. (1976) · British Journal of Haematology · doi:10.1111/j.1365-2141.1976.tb03563.x · Cited by 5,602
Reinherz, E. L., Kung, P. C., Goldstein, G., Levey, R. H., & Schlossman, S. F. (1980) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.77.3.1588 · Cited by 1,630
The differentiation and function of human T lymphocytes
Reinherz, E. L., & Schlossman, S. F. (1980) · Cell · doi:10.1016/0092-8674(80)90072-0 · Cited by 1,530
Tyrosine Kinase Activity and Transformation Potency of bcr-abl Oncogene Products
Lugo, T. G., Pendergast, A.-M., Muller, A. J., & Witte, O. N. (1990) · Science · doi:10.1126/science.2408149 · Cited by 1,281
Civin, C. I., Strauss, L. C., Brovall, C., Fackler, M. J., Schwartz, J. F., & Shaper, J. H. (1984) · The Journal of Immunology · doi:10.4049/jimmunol.133.1.157 · Cited by 1,202
Identification of a putative second T-cell receptor
Brenner, M. B., McLean, J., Dialynas, D. P., Strominger, J. L., Smith, J. A., Owen, F. L., Seidman, J. G., Ip, S., Rosen, F., & Krangel, M. S. (1986) · Nature · doi:10.1038/322145a0 · Cited by 996
Tkachuk, D. C., Kohler, S., & Cleary, M. L. (1992) · Cell · doi:10.1016/0092-8674(92)90602-9 · Cited by 920
Terstappen, L., Huang, S., Safford, M., Lansdorp, P., & Loken, M. (1991) · Blood · doi:10.1182/blood.v77.6.1218.1218 · Cited by 847
Cited by
Pui, C.-H., & Evans, W. E. (1998) · New England Journal of Medicine · doi:10.1056/nejm199808273390907 · Cited by 832
Self-citationRecent Advances in Flow Cytometry: Application to the Diagnosis of Hematologic Malignancy
Jennings, C. D., & Foon, K. A. (1997) · Blood · doi:10.1182/blood.v90.8.2863 · Cited by 447
Schrappe, M., Valsecchi, M. G., Bartram, C. R., Schrauder, A., Panzer-Grümayer, R., Möricke, A., Parasole, R., Zimmermann, M., Dworzak, M., Buldini, B., et al. (2011) · Blood · doi:10.1182/blood-2011-03-338707 · Cited by 435
Pui, C.-H. (1995) · New England Journal of Medicine · doi:10.1056/nejm199506153322407 · Cited by 379
Self-citationAmylon, M., Shuster, J., Pullen, J., Berard, C., Link, M., Wharam, M., Katz, J., Yu, A., Laver, J., Ravindranath, Y., et al. (1999) · Leukemia · doi:10.1038/sj.leu.2401310 · Cited by 347
Metadata
- Authors
- Pui, C., Behm, F., & Crist, W.
- Venue
- Blood
- Publisher
- American Society of Hematology
- Published
- 1993-07-15
- Volume
- 82
- Issue
- 2
- Pages
- 343-362
- ISSN
- 0006-4971 (ISSN-L)
- 1528-0020
- OpenAlex
- W2236639694
- Cited by
- 315
- References
- 117
- FWCI
- 25.73
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Clinical and biologic relevance of immunologic marker studies in childhood acute lymphoblastic leukemia. https://app.cochat.ai/papers/10.1182/blood.v82.2.343.343
- The paper
- Pui, C., Behm, F., & Crist, W. (1993). Clinical and biologic relevance of immunologic marker studies in childhood acute lymphoblastic leukemia. Blood. https://doi.org/10.1182/blood.v82.2.343.343
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.